Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05789303RecruitingPhase 2
Belantamab plus other medicines for relapsed multiple myeloma
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
Chicago, IllinoisAges 18 years+ - NCT05789030Recruiting
Treating IgG4-related disease with mild steroid starts
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
BeijingAges 18–75 - NCT05789901Recruiting
Using a Facebook chatbot to share health information
This study tests whether a Facebook Messenger chatbot can provide helpful health information for different conditions. You may help researchers check if people can use the chatbot and understand the information.
Montreal, QuebecAges 14 years+ - NCT05790330Recruiting
Study brain–skin links in teenagers with eczema
This study looks at how eczema may be connected to the brain and sleep, using questionnaires and MRI scans. It may help researchers understand what drives symptoms and how treatments could be improved.
LondonAges 12–18 - NCT05790356Recruiting
Fecal transplant to treat rheumatoid arthritis symptoms
This study tests whether transferring stool from a screened healthy donor into the gut can improve rheumatoid arthritis (RA) in people whose RA is in remission or low activity. It’s mainly trying to change the gut bacteria to reduce RA symptoms or flare-ups.
London, OntarioAges 18 years+ - NCT05790785Recruiting
Tests blood vessel changes in kids soon after type 1 diabetes
This study looks at how blood vessels and blood pressure change in children soon after being diagnosed with type 1 diabetes. It may help doctors better understand early vascular risk and how to monitor it.
Vancouver, British ColumbiaAges 8–18 - NCT05791162Recruiting
Looking at immune cell ratios in IgA kidney disease
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
BesançonAges 18 years+ - NCT05792007Recruiting
Study of bone marrow environment in childhood leukemia
This study looks at what the bone marrow “microenvironment” is like in children newly diagnosed with acute leukemia, to better understand the disease. It also compares leukemia samples to samples from children having certain orthopedic surgery.
ToursAges 1–15 - NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT05797272Recruiting
In-utero stem cell treatment for Bart’s hydrops
This trial studies whether giving hematopoietic (blood-forming) stem cells while the baby is still in the womb can treat fetuses with Bart’s hydrops fetalis syndrome. It aims to improve outcomes after prenatal intervention in carefully selected pregnancies.
ShatinAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT05806580RecruitingPhase 4
Second relma-cel infusion for returning B-cell lymphoma
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05807256Recruiting
Fertility treatments for people with immune system joint diseases
This trial looks at fertility (“medically assisted fertilization,” such as IVF) for people with certain immune-related rheumatology conditions (like lupus, rheumatoid arthritis, or vasculitis). It may help patients and their clinicians understand which fertility approach works best and is safe for this group.
MilanAges 18–50 - NCT05807867Recruiting
Support program to help women with HIV keep treatment working
This study tests a stigma-reducing support program to help women living with HIV and serious mental illness stay adherent to HIV treatment. It focuses on sustaining viral suppression by addressing stigma that can make care harder, and it involves family and community leaders as part of the approach.
GaboroneAges 18–65 - NCT05809180Recruiting
Tested chemo regimen for newly diagnosed older adults with DLBCL
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
Suzhou, JiangsuAges 70 years+ - NCT05811013Recruiting
Static magnetic brain stimulation for progressive multiple sclerosis
This trial studies whether a noninvasive brain stimulation approach using a static magnetic field can help people with progressive multiple sclerosis. It aims to improve progressive nerve function while keeping other treatments stable.
Pozzilli, IserniaAges 18–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.